Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is why Nuvilex and it's proprietary cellulose-based live-cell encapsulation is the future of cancer and diabetes treatments:
From rudygerner almost a year ago...
Capsules composed of cellulose sulphate and polydimethyldiallyl ammonium have excellent mechanical properties and can be manufactured to consistent diameter and pore size.
The encapsulated cells can be cultivated in a normal cell culture medium (the nature of which depends on the encapsulated cells) at standard conditions of humidity, temperature and CO2 concentration. During this culture period production of antibodies from the capsules into the cell culture medium can be demonstrated with either Western Blot or Elisa technology using specific antigens and can furtheron be quantitated using second antibodies conjugated to fluorogenic dyes.
After a suitable period in culture (normally not less than 1 hour and not exceeding 30 days), the cell containing capsules can be surgically implanted either directly, or by injection using a syringe into various areas of the body.
The antibodies produced by the encapsulated cells according to the invention can be based on any immunglobulin class useful for therapy, including but not limited to genetically modified antibodies.
The encapsulated cells according to the invention can be cells taken from patients or from any other source, including human and animal cells, that have been genetically modified for the production of cloned antibodies.
The encapsulated cells and capsules, respectively, are especially used for the implantation into a living animal body, including a human, for the treatment of diseases or disorders responsive to the antibodies released from said capsules. After implantation of capsules into an animal body intraperitoneally and subcutaneously it has been found that the capsules, especially cellulose sulphate capsules, offer an obvious advantage with respect to mechanical resistance over, for instance, alginate capsules since there are found intact as long as 10 months post-implantation regardless of whether they are implanted subcutaneously or intraperitoneally.
Additionally, it has been observed that subcutaneous and intraperitoneal implantations of cell-containing cellulose sulphate capsules revealed differences with respect to at least two points. First, the amount of antibody released in the bloodstream was markedly higher in the former situation. A very likely explanation for this difference resides in the fact that capsules are rapidly vascularized when implanted subcutaneously and are not vascularized at all when implanted intraperitoneally. The beneficial effect of vascularization might be two-fold, firstly facilitating antibody uptake by blood and, secondly, ensuring a better supply of nutrients favoring cell survival since viability of cells within intraperitoneally implanted capsules was reproducibly observed to be lower. In addition to extensive vascularization, which showed no significant alteration over the 10 months of the follow-up, the clustering of cells within a connective pouch after subcutaneous implantation would allow removal of capsules through an easy onestep surgical ablation of the whole neorgan should this prove necessary. Finally, it is important to underline that development of isolating fibrosis around implanted cellulose sulphate capsules is not systematic. This observation contrasts with what has been reported in the case of alginate-poly(L)-alginate microcapsules around which a host reaction with fibrosis developed probably as a result of potent macrophage activation by the encapsulating polymer (Pueyo, M. E, et al., J. Biomater Sci. Polym. Ed., Vol. 5, 197-203 (1993)).
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=102458582
Rudy, great DD. This is important information that every shareholder should have...
Hey Bill, this little OTC biotech should make anyone nervous who is betting against it. :)
Interesting and I feel like I've lived through plenty of these examples... True story or not, elements are evidently true, imo...
I am not worried. Why would FDA grant ODD if there were issues? I think Dr Von Hoff helped with FDA. He has a vested interest in making the FDA aware of CiaB technology. We have a small staff, lots of irons in the fire, Two concurrent studies and limited funding...
We just applied for and received ODD from the FDA for Pancreatic Cancer last quarter.
True... A long line of super stars...
Cell-in-a-Box is the delivery systems for these B cells, Melligen cells. If it works, no need for insulin anymore...
http://www.docstoc.com/docs/29314924/Melligen-Cells-Physiological-Insulin-Secretion-from-a-novel-human
Here is the Ann Simpson peer reviewed article in the treatment PMCB will be using for diabetes.
http://www.nature.com/gt/journal/v22/n1/full/gt201493a.html
PharmaCyte Biotech Diabetes Consortium Member Publishes Review Article on Use of Genetic Engineering to Treat Diabetes
SILVER SPRING, Md., Feb. 13, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today reported that its partner, the University of Technology Sydney (UTS), has published a review article on cell and gene therapies for the treatment of diabetes. The publication, titled "The use of ß-cell transcription factors in engineering artificial ß cells from non-pancreatic tissue," which was authored by a member of PharmaCyte Biotech's Diabetes Consortium, Prof. Ann M. Simpson and her colleagues at UTS, appeared in the prestigious Nature publishing group scientific journal Gene Therapy. This review can be located by clicking here.
The article reports that cell and gene therapies have shown promise as a potential cure for Type 1 diabetes through the genetic engineering of non-pancreatic cells that makes them capable of regulating blood glucose levels by producing insulin on demand. Such genetic modification and augmentation of non-pancreatic cells has the ultimate goal of producing glucose-responsive "artificial" ß insulin-producing cells that mimic the function of pancreatic ß cells in non-diabetic individuals.
Using some of the technology discussed in the review article, Prof. Simpson and her colleagues have developed the Melligen cell line, a human non-pancreatic cell line that originated from liver cells that were genetically engineered to produce and store insulin and secrete it at levels in proportion to the levels of glucose (blood sugar) in the human body. The Melligen cell line is currently undergoing an initial evaluation for its utility in PharmaCyte Biotech's Cell-in-a-Box®-based treatment of diabetes, the first of a number of preclinical studies that will be performed by PharmaCyte Biotech's international Diabetes Consortium.
Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech, said, "We are delighted by this important publication from one of the key members of our international Diabetes Consortium. Prof. Simpson is a world-renowned scientist in the field of diabetes and, as this publication shows, is at the forefront of research into finding a cure for this disease."
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech's treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This "targeted chemotherapy" has proven remarkably effective in past clinical trials. PharmaCyte Biotech is also working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors. In addition, PharmaCyte Biotech is developing treatments for cancer based upon chemical constituents of the Cannabis plant, known as cannabinoids. In doing so, PharmaCyte Biotech is examining ways to exploit the benefits of Cell-in-a-Box® technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides PharmaCyte Biotech the rare opportunity to develop "green" approaches to fighting deadly diseases, such as cancer of the pancreas, brain and breast, which affect hundreds of thousands of individuals worldwide every year.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte Biotech or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte Biotech, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte Biotech's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte Biotech's intellectual property and PharmaCyte Biotech's continued ability to raise capital. PharmaCyte Biotech does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte Biotech can be found at www.PharmaCyteBiotech.com. It can also be obtained by contacting Investor Relations.
CONTACT: Investor Relations Contacts:
Jamien Jones
Blueprint Life Science Group
Telephone: 415.375.3340 Ext. 103
jjones@bplifescience.com
http://money.cnn.com/news/newsfeeds/articles/globenewswire/10120121.htm
I can understand that sentiment because the cheaper the price, the more shares you get for your dollar.
IMO, this is a bargain price anywhere under $1 and certainly here, in the teens.
I had some extra funds a while back and decided to look for a different bio, been here almost a year.
I could not find anything that even closely compares to what we have with Cell in a Box(R) technology, especially at this price.
At some point, they will not be able to hold this price down. When we get study results and start hitting Phase I/II milestones with the TD2/Von Hoff study, and we already have ODD and also said we intend to fast track... In time, more institutional investors will take notice...
Anyway, whatever you pay now, there is potential for a huge return. You just have to be patient. This is a bio, studies, trials and reported results take time... And, with all that said, things can change overnight...
Nice one Marleebone and you just may be right...
Naked short interest has significantly dropped, at least according to the last report.
http://www.otcmarkets.com/stock/PMCB/short-sales
However, daily short interest is still very high. Traders are obviously still interested in this as a short play.
http://otcshortreport.com/index.php?index=Pmcb&action=view#.VNzzEIY76rU
These 2 recorded interviews will provide a lot of background info.
We now have FDA ODD and the initial studies with Dr Von Hoff went well. That is why we are starting a 13 treatment study for malignant ascites. As Ken W said, "To our knowledge, there is no other treatment on the market that can accomplish this - particularly in the case of advanced cancers."
A good investment, imo, especially for the long term.
http://www.nasdaq.com/press-release/pharmacyte-biotechs-expanded-followup-study-on-malignant-ascites-fluid-accumulation-in-final-stage-20150126-00537#ixzz3RUzWwQCI
http://www.stockmarketmediagroup.com/wp-content/uploads/2013/10/NVLX-COO-Interview-Dr.-Gerald-Crabtree.mp3
http://www.stockmarketmediagroup.com/wp-content/uploads/2014/06/NVLX-CEO-COO-Interview.mp3
Just to be clear, both diabetes and pancreatic cancer are related as they both involve the pancreas. Main principle...
The ODD we received was for pancreatic cancer. Diabetes has been a focus for the company since we received rights from Austrianova, 2013. We are just now beginning our new studies with the Mellegen cells. This is good news. It should be a main topic of conversation right now. Why steal it's time on stage?
Well, it is certainly not the only use for Cell-in-a-Box(R) technology. Having done your DD, you know that. We, like many other bios, now have a couple of studies going on and neither is for pancreatic cancer. We received ODD from the FDA for PC because of the previous trials with Austrianova. For almost the past year, yeahright, we have been working with Dr Von Hoff on "quality of life" improvements by treating malignant ascites for all abdominal cancers.
The mult-focus should not come as a surprise and, imo, is good for the company and shareholder. I believe CiaB will revolutionize many of today's treatments.
I am not interested in downplaying any of CiaBs treatments. Not sure why any LONG would want to do that...
Thanks, Bill. The number of stars indicates how many of the top 50 followed Ihub members have posted on the particular board in the last 24 hours.
Fisher Asset Management LLC has been holding a very small amount of shares since 2013. Last quarter they added 220 more. :). Others have come and gone but they have continued to keep us on their radar.
http://finance.yahoo.com/q/mh?s=PMCB+Major+Holders
I am not a star either, Bill. These guys have over 1700 followers each. I think they are good chartists and probably have some success trading. I just saw the indicator above and was curious what it meant. You don't see it often except on trader specific boards.
Dr Brandtner cowrote the following book...
Bioencapsulation of Living Cells for Diverse Medical Applications
http://ebooks.benthamscience.com/book/9781608057207/
PMCB has a 3 star rating which you will see at the top of the ibox. Three of the most followed investors have posted on this board in the last 24 hours, janice shell being one of them. Interesting...
Thanks rudy, I do believe this treatment is truly revolutionary. Your DD just helps to boost shareholder confidence...
Very interesting, Pete. But as I once heard in a movie about horse racing, "You can't play them all. That would be cheating." :)
I like everything about PharmaCyte especially our CEO and all the world renowned doctors involved. The technology, I believe is revolutionary as well but it is going to take this team of doctors and executives for us to realize success.
I am a PMCB fan. I stand firm... :)
Here is a nice short video about Cell in a Box. It was done when we were still under the Nuvilex name...
I could not agree more efood. Great post!
As usualy, avobill, you are a true assett to this team. Thanks for your DD....
I think CNN Money would disagree. They thought it newsworthy enough to pick up the story. I have never seen them share a pump article before. They share stories that are newsworthy and important to investors. And, Like all the stars on this team, they also have a reputation to protect.
Attempts to discredit this company are sounding more and more ridiculous...
:). Let's just talk about diabetes for a minute. I know this article is a paid for article so let's just get that matter out the way... Nonetheless, the information here should encourage all investors... And btw, CNN Money picked it up so I imagine they believe this information is news worthy, and it is...
PharmaCyte Biotech's Diabetes Treatment: How Would It Work?
Marketwired
February 06, 2015: 09:00 AM ET
PharmaCyte Biotech, Inc. (OTCQB: PMCB) -- How much would a cure for diabetes be worth? It's incalculable, but certainly many billions of dollars. Consider the insulin market alone is over $25 billion annually and projected to reach $40 Billion by 2018. Diabetes is a worldwide epidemic with over 350 million diabetes patients globally and growing.
A lot has been made of PharmaCyte Biotech's (OTCQB: PMCB) pending Phase 2b FDA clinical trial for Pancreatic Cancer. However, the use of their Cell-in-a-Box® technology as a potential treatment for Diabetes is not well understood.
Let's clear it up.
Diabetes occurs when the Pancreas fails to produce Insulin, or when the insulin it does produce is not effectively used by the body. Insulin regulates high levels of sugar in our blood stream.
High blood sugar leads to excessive thirst, unusual weight gain, fatigue, weakness, fainting spells, nausea, blurred vision, infections, poor healing, itching, and nerve pain.
The symptoms of Diabetes are now controlled through diet, exercise, medication, and insulin.
PharmaCyte Biotech's Cell-in-a-Box® representsa potential opportunity for an implantedcellulose-based capsule filled with live cells capable of producing insulin, to mirror the activity of a normal pancreas and make, store and deliver the proper dosages of insulin into the blood stream, thereby controlling blood sugar levels.
Earlier this week, PharmaCyte Biotech announced its proprietary Melligen cell line developed by Prof. Ann Simpson of the University of Technology, Sydney, is being used in a preclinical study. The Melligen cell line was encapsulated by PharmaCyte, and is being introduced in mice to evaluate the safety, efficacy and dosing of its Melligen cell line for the treatment of diabetes.
These Melligen cells produce and store insulin, and secrete it at levels in proportion to the body's glucose needs. The theory is they could mirror the workings of a functioning pancreas. This is the first time PharmaCyte Biotech will employ cells derived from humans in a preclinical study.
In a past preclinical study, live pancreatic islet cells from pigs were encapsulated using the Cell-in-a-Box® technology and implanted in diabetic rats. These Islet cells produced insulin and behaved like a normally functioning pancreas.
This past "Proof of Principle" study in rats produced absolutely astounding results. After the cells were implanted, the blood glucose levels of the rats normalized and remained that way for the six month duration of the study.
When the cellulose based capsules were removed from the rats at the end of the study, they were found to be fully viable and capable of responding to changes in blood glucose levels in their surroundings. The live pancreatic islet cells functioned like a normal pancreas.
Much like the pancreatic islet cells from pigs, PharmaCyte Biotech is hopeful that the implantation of its Melligen cell line using Cell-in-a-Box® will represent a potential treatment for diabetes.
The American Diabetes Association estimates the annual cost to treat Diabetes in the US alone is about $260 Billion.
Put whatever number you want on it. Whatever it is, the mere possibility of an effective treatment could be worth billions to the value of the company as more study data becomes available and the market starts to recognize the possibilities.
"Ownership of shares in PharmaCyte Biotech (PMCB) represent the possibility to participate in a potential treatment for Diabetes, along with a therapy for Pancreatic Cancer.
"Rarely can investors find a way to participate in this sort of upside potential for a mere $.10 to $.15 per share.
"The risk/reward equation here is impressive, especially for those investors with a multi-year time horizon. A little capital could go a long way in PharmaCyte Biotech," says Larry Isen, Editor and Publisher of the OTC Journal.
About the OTC Journal
The OTC Journal has been published continuously for 17 years, and is the longest running electronic newsletter devoted to small and microcap stocks. To subscribe for free, simply go to www.otcjournal.com and input your email address. To receive an IM or Text Version, simply text the word PROFITS to 86677.
DISCLAIMER
The OTC Journal Newsletter is an electronic publication committed to providing our readers with useful information on publicly traded companies. The Newsletter contracts with publicly traded companies or third parties and receives compensation from them as payment for publishing information and opinions about the company and the trading market for their securities. These publications should not be considered to be independent publications concerning the company.
http://money.cnn.com/news/newsfeeds/articles/marketwire/11G032536-001.htm
Thanks B Free...
The name change was a positve move for many reasons. Nuvilex was the name used previously which represented the previous business. As you know, when we got Cell in a Box(R) technology it changed everything. The new name is more representative of our business as a biotech. It should have also helped to expose any naked shorts out there.
Unless you need the money soon, which most longs do not, why would you care about the pps? The science is right on track and doing well. Do yourself a favor, don't worry about the day to day pps if you are long. It is not controlled by the company and we don't have the financials or the product on the market to support stability and big investors yet, so the pps is going to fluctuate.
Follow the progress of the science and you will be fine.
On that we do agree. Those who benefit from the volatility created are not longs or the company. Just traders who ride the waves...
Wow, yeahright, I am surprised. I told you true longs would stand out. Longs stand for something and don't just fall for anything. If a name change causes concern than I think you have truly missed the vision of this company.
I grant you that. I do think Dr Von Hoff is on the one hand an idealist, and on the other hand, capable of making an ideal real.
He wants to help all patients with abdominal cancers to improve thier quality of life by treating malignant ascites. And he has FDA successes as well as experience. You can hear the passion he has for patients.
He has never given up on finding a cure and may have stumbled onto something we never expected, making inoperable pancreatic cancer operable by treating ascites associated with all abdominal cancers.
Actually, I think it was you who brought up the pps saying the market is proving the company is not a worthy investment.
I was just providing my perspective and one that has been validated by professionals. Shorts write articles to scare small investors for personal gains.
To say it is just blaming is like saying, "don't blame eating all that chocolate on your being fat".
It is what it is...
http://ajrarchive.org/Article.asp?id=4911
Articles report on the technology and the best articles are scientic ones. One is provided below.
Btw, three of the doctors who wrote this article are now on the PharmaCyte team, Gunzburg, Salmons and Lohr.
That gives you a clue. Another thing to take into consideration is TD2's interest in what this technology can accomplish. They are starting an extended study for malignant ascites. Then, it will be followed up with human clinical trials architecturally designed by Dr Daniel Von Hoff and others from his team.
I know some are very familiar with this info but please bear with me. I am providing it again for anyone who may not be aware. Note, this PR was picked up by Nasdaq. I don't think they are in the business of sharing corporate updates from scam companies...
PharmaCyte Biotech's Expanded Follow-up Study on Malignant Ascites Fluid Accumulation in Final Stages of Preparation
SILVER SPRING, Md., Jan. 26, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box®, today reported that preparations for an expanded, follow-up study of the effectiveness of its pancreatic cancer treatment (a combination of low doses of the cancer prodrug ifosfamide and Cell-in-a- Box® capsules containing live cells capable of converting ifosfamide into its cancer-killing form) on the accumulation of malignant ascites fluid are in their final stages. This preclinical study will be conducted by Translational Drug Development (TD2) in the United States. Pancreatic cancer expert Dr. Daniel D. Von Hoff is the Chief Development Officer of TD2 and a principal architect of the study. It is expected that the study will begin in approximately two weeks.
This expanded study is designed to build upon the successful results of the pilot study that was completed by TD2 late last year. In that study, mice bearing an aggressive human ovarian cancer (ES-2), which produces significant amounts of malignant ascites fluid, were divided into 4 groups with 10 mice in each group. The mice in Group 1 served as a control group. Group 2 was made up of mice treated with PharmaCyte Biotech's pancreatic cancer treatment. Group 3 was treated with cisplatin, a chemotherapy drug often used to treat ovarian cancer. Group 4 was treated with a combination of PharmaCyte Biotech's pancreatic cancer treatment and cisplatin.
The new expanded study will use the same ES-2 ovarian cancer model, but in this study, the mice will be divided into 13 different treatment groups with 10 mice in each group. This study is designed to better define the parameters that will be needed to design a future Phase 1 clinical trial in humans that suffer from malignant ascites fluid accumulation as a result of their abdominal cancers, such as pancreatic, liver, ovarian, uterine and colon.
Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech, said, "We are looking forward to this expanded preclinical study of the effectiveness of our pancreatic cancer treatment in reducing the rate of malignant ascites fluid accumulation in the abdomen. If successful, it could quickly lead to a clinical trial in patients with abdominal tumors who suffer from this very serious cancer-associated malady. The accumulation of ascites fluid is problematic for patients with an abdominal cancer because it's very painful and can cause breathing problems. Once it gets to a certain stage, it must be removed on a regular basis. This procedure in itself is very uncomfortable for patients and costly. Hopefully, our pancreatic cancer treatment will slow the accumulation of this malignant ascites fluid and thus reduce the number of withdrawals of the fluid that are needed over a given period of time. To our knowledge, there is no other treatment on the market that can accomplish this - particularly in the case of advanced cancers."
http://www.nasdaq.com/press-release/pharmacyte-biotechs-expanded-followup-study-on-malignant-ascites-fluid-accumulation-in-final-stage-20150126-00537
http://www.mdpi.com/1999-4923/6/3/447
Trader, I would if I could but Scotty only lets you do it for 4x the amount of the current pps. I know nothing big is expected to happen before trials but I am too cautious about losing the few shares I have.
But for those who can put in a sell order with which they are comfortable, it is a great counter tactic. :)
Jan 5 closed @ .20
Jan 6 Short article from Seeking Alpha
Jan 8, 15 and 21 more Seeking Alpha articles discrediting PHarmaCyte.
Volume increased with major selling and on January 22, with over 8 million shares traded, the price was down to .1365.
Very well orchestrated in my opinion. Many traders follow SA and believed so much that many may have sold at a loss. This is what concerns me. Desperation calls for desperate measures. Appears desperation was most assuredly at play and that is understandable.
The company is achieving many milestones and not everyone is happy about that. However, the average shareholder is hurt, the company is damaged and it makes it even more of a challenge to get funds needed for business operations.
Just my opinion and I will be holding for the science which is not reflective of the current pps. All this pps tells us is we don't have big investors in yet and we have a lot of traders. Typical for the OTC.
The science will set us apart soon enough. This article pretty much sums up what I think is happening here. Fortunately, we have Dr Von Hoff driving the science and he has many connections. This too shall pass..
http://ajrarchive.org/Article.asp?id=4911
I am providing evidence for people to discern for themselves and I will provide it again as there is no intent on my part to mislead anyone.
AustriaNova conducted trials years ago but went bankrupt and was unable to compete them. We bought exclusive rights for CiaB' use for oncology and diabetes.
Austrianova's trials beat the gold standard in those trials. In recent studies we also did well against the current standard ovarian cancer in testing for malignant ascites... and are now starting a 13 treatment extended study with TD2 in preparation for clinical trials.
And all bios "play around" with mice as you put it. This must be done before human trials and is called a clinical study. Understanding how bios work will help with some of the confusion here.
http://www.mdpi.com/1999-4923/6/3/
http://www.genetherapy.me/cell-therapy/nuvilex-announces-preliminary-data-from-preclinical-study-of-effects-of-its-pancreatic-cancer-treatment-on-ascites.php
http://www.nasdaq.com/press-release/pharmacyte-biotechs-expanded-followup-study-on-malignant-ascites-fluid-accumulation-in-final-stage-20150126-00537
http://www.sec.gov/Archives/edgar/data/1157075/000115707513000007/a3rdfaddnvlx2013.htm
http://www.nuvilex.com/latest-news/24-nuvilex-inc-restructures-corporate-operations-to-reflect-biotechnology-focus
I know you are Pete and thank you very much. If I had the funds, I'd be buying everyday too...
True dat but when the technology is proven with current studies and upcoming trials, they will come. Until then, traders are controlling the pps. Longs are holding and traders can have their fun on the penny trades. Longs sit back, watch, relax (because the science is doing well) and we wait for dollars.
Easy...